Loading this company
Novavax, Inc.
NVAXPrices in USD
TickerWorth ScoreC47/100
What we think
Priced below our one model’s value of $15.44.
Price
$11.09USD down −$0.17 (−1.55%)
Quoted · Prices are delayed.
Showing the last price we hold for this listing, recorded 2026-10-19 15:55 UTC (3 hours ago).
Why did it move today?
Nothing we can cite explains today’s move for this company.
Is it cheap?
One model only, on today’s numbers
$15.44
Led by peer multiples (P/E, EV/EBITDA, P/S) · Fast grower
Price $11.09Priced · Prices are delayed.
Changing the inputs, and every lens with its working, is part of Pro. See plans
Is it a good business?
- Growth0 out of 100
- Financial health100 out of 100
- Past performance50 out of 100
Bull, base, bear
Our forward range over 12 months is part of Pro. See plans
The street
Analysts’ mean target
$14.22 across 9 analysts
The high and low of the analyst range is part of Pro. See plans
What does it do?
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It operates in the Biotechnology industry (Healthcare sector), headquartered in United States. The company employs roughly 749 people.
Key stats
52-week range$6.20–$13.39
- Open
- $11.21
- Day high
- $11.97
- Day low
- $11.08
- Previous close
- $11.26
- Volume
- 2,483,156 · 0.42× avg
- Average volume
- 5,865,723
- Market cap
- $1,828,423,424.00
- P/E (TTM)
- —
- Earnings per share
- −$1.58
- Beta
- 2.44
Prices are delayed. The feed does not say when these figures were taken.
What’s the latest?
- Reported quarterly or annual results
- Reported shareholder vote results
- Reported quarterly or annual results
- Reported quarterly or annual results
- Signed a material agreement
- Reported quarterly or annual results
- Reported quarterly or annual results
Top news
No recent headlines we can cite for this company.
Insider trades
The 90-day buying-and-selling read is part of Pro. See plans
- Rodgers Richard JOption exercise · —
- King Rachel K.Option exercise · —
- DOUGLAS RICHARD
Not investment advice. TickerWorth Score is a model output.